(Corrects third paragraph to say India has partially or fully immunised only 9.5% of its 1.35 billion people, not 12%.)
By Krishna N. Das
NEW DELHI (Reuters) - India's daily COVID-19 shots have fallen sharply from an all-time high reached early last month as domestic companies struggle to boost supplies and imports are limited, even as the country fights the world's worst surge in infections.
Daily inoculations have averaged 2.5 million since hitting a peak of 4.5 million on April 5. A quadrupling of coronavirus cases during the period has collapsed the public health system in many regions of the country.
India, with the world's biggest vaccine making capacity, has partially or fully immunised only 9.5% of its 1.35 billion people, according to data from the government's Co-Win https://dashboard.cowin.gov.in portal.
Public forecasts by its only two current vaccine producers show their total monthly output of 70-80 million doses would increase only in two months or more, though the number of people eligible for vaccines has doubled to an estimated 800 million since May 1.
India on Saturday received 150,000 doses of Russia's Sputnik V vaccine and the government said "millions of doses" more will come in.
Pfizer said on Monday it was in discussions with the Indian government seeking an "expedited approval pathway" for its vaccine.
"Unfortunately, our vaccine is not registered in India although our application was submitted months ago," CEO Albert Bourla said.
"We are currently discussing with the Indian government an expedited approval pathway to make our Pfizer-BioNTech vaccine available for use in the country."
Pfizer was the first company to seek emergency use authorisation for its vaccine in India late last year. It withdrew its application in February after the drugs regulator sought a small, local safety study for the shot before considering its request.
But as cases surged, India said last month it would fast-track approval for some foreign shots, with companies now required to do a local trial https://pib.gov.in/PressReleaseIframePage.aspx?PRID=1711979 within 30 days of approval, not before.
GlobalData analyst Prashant Khadayate said Pfizer will become a "vaccine of choice among people who can afford it" but that its need to be stored in ultra-low temperatures would be a challenge.
India has also invited Johnson & Johnson and Moderna to sell their vaccines to the country.
(Reporting by Krishna N. Das; Additional reporting by Manash Mishra; Editing by Tom Hogue and Nick Macfie)
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU